337 related articles for article (PubMed ID: 33139041)
21. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
[TBL] [Abstract][Full Text] [Related]
22. A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer.
Gibbs DD; Pyle L; Allen M; Vaughan M; Webb A; Johnston SR; Gore ME
Br J Cancer; 2002 May; 86(9):1379-84. PubMed ID: 11986767
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.
Gordon AN; Hancock KC; Matthews CM; Messing M; Stringer CA; Doherty MG; Teneriello M
Gynecol Oncol; 2002 Apr; 85(1):129-35. PubMed ID: 11925132
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer.
Broekman KE; Hof MAJ; Touw DJ; Gietema JA; Nijman HW; Lefrandt JD; Reyners AKL; Jalving M
Invest New Drugs; 2020 Oct; 38(5):1454-1462. PubMed ID: 32146550
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
26. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
[TBL] [Abstract][Full Text] [Related]
27. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
[TBL] [Abstract][Full Text] [Related]
29. A phase I/II dose escalation study of carboplatin in the treatment of newly diagnosed patients with advanced ovarian cancer receiving paclitaxel.
Gordon AN; Hancock KC; Matthews CM; Stringer CA; Boston J; Nemunaitis J
Am J Clin Oncol; 1999 Dec; 22(6):601-5. PubMed ID: 10597745
[TBL] [Abstract][Full Text] [Related]
30. Increased incidence of severe gastrointestinal events with first-line paclitaxel, carboplatin, and vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer.
Mendivil AA; Micha JP; Brown JV; Rettenmaier MA; Abaid LN; Lopez KL; Goldstein BH
Int J Gynecol Cancer; 2013 Mar; 23(3):533-9. PubMed ID: 23385285
[TBL] [Abstract][Full Text] [Related]
31. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.
Morgan MA; Sill MW; Fujiwara K; Greer B; Rubin SC; Degeest K; Yamada SD; Waggoner S; Coleman RL; Walker JL; Mannel RS
Gynecol Oncol; 2011 May; 121(2):264-8. PubMed ID: 21277623
[TBL] [Abstract][Full Text] [Related]
32. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gould N; Sill MW; Mannel RS; Thaker PH; Disilvestro P; Waggoner S; Yamada SD; Armstrong DK; Wenzel L; Huang H; Fracasso PM; Walker JL
Gynecol Oncol; 2012 Apr; 125(1):54-8. PubMed ID: 22155262
[TBL] [Abstract][Full Text] [Related]
33. A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study.
Tiersten AD; Sill MW; Knight D; Muggia F; Garcia AA; Swensen R; Warshal DP; Mannel RS; Fracasso PM
Gynecol Oncol; 2010 Sep; 118(3):303-7. PubMed ID: 20547415
[TBL] [Abstract][Full Text] [Related]
34. Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer.
Micha JP; Goldstein BH; Mattison JA; Bader K; Graham C; Rettenmaier MA; Brown JV; Markman M
Gynecol Oncol; 2005 Jan; 96(1):132-5. PubMed ID: 15589591
[TBL] [Abstract][Full Text] [Related]
35. Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma.
Azmi AS; Khan HY; Muqbil I; Aboukameel A; Neggers JE; Daelemans D; Mahipal A; Dyson G; Kamgar M; Al-Hallak MN; Tesfaye A; Kim S; Shidham V; M Mohammad R; Philip PA
Clin Cancer Res; 2020 Mar; 26(6):1338-1348. PubMed ID: 31831564
[TBL] [Abstract][Full Text] [Related]
36. Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.
Gounder MM; Zer A; Tap WD; Salah S; Dickson MA; Gupta AA; Keohan ML; Loong HH; D'Angelo SP; Baker S; Condy M; Nyquist-Schultz K; Tanner L; Erinjeri JP; Jasmine FH; Friedlander S; Carlson R; Unger TJ; Saint-Martin JR; Rashal T; Ellis J; Kauffman M; Shacham S; Schwartz GK; Abdul Razak AR
J Clin Oncol; 2016 Sep; 34(26):3166-74. PubMed ID: 27458288
[TBL] [Abstract][Full Text] [Related]
37. A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).
Horinouchi H; Yamamoto N; Nokihara H; Horai T; Nishio M; Ohyanagi F; Horiike A; Nakagawa K; Terashima M; Okabe T; Kaneda H; McKee MD; Carlson DM; Xiong H; Tamura T
Cancer Chemother Pharmacol; 2014 Jul; 74(1):37-43. PubMed ID: 24807459
[TBL] [Abstract][Full Text] [Related]
38. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
Cognetti F; Bagnato A; Colombo N; Savarese A; Scambia G; Sehouli J; Wimberger P; Sorio R; Harter P; Mari E; McIntosh S; Nathan F; Pemberton K; Baumann K
Gynecol Oncol; 2013 Jul; 130(1):31-7. PubMed ID: 23234805
[TBL] [Abstract][Full Text] [Related]
39. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
[TBL] [Abstract][Full Text] [Related]
40. The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Hanaoka T; Hasegawa K; Fujiwara K
Int J Gynecol Cancer; 2016 Mar; 26(3):443-8. PubMed ID: 26807640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
